Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions for which limited or no current therapies exist.

from http://www.edgetherapeutics.com/about/

Overview

Total FundingEmployeesLast Funding DateStatus
$101,472,50011-502015-04-09Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-12-01$16,500,000Series C
2012-09-17$118,500Series Unknown
2011-06-24$219,500Series Unknown
2010-05-03SeedNew Jersey Economic Development Authority
2013-06-04$18,000,000Series CMaxim Group
2014-09-08$10,000,000Debt FinancingHercules Capital, Inc.
2015-04-09$56,000,000Series CVenrockJanus Capital Group, BioMed Ventures, New Leaf Venture Partners, Sofinnova Ventures, Franklin Advisors
2010-11-08$634,500Series A

SEC Form D Funding Events

DateOfferedSoldType
2015-04-09$56,000,000$55,999,978Equity
2014-11-13$25,000,000$7,937,236Equity
2013-03-25$20,000,000$6,673,405Equity
2012-09-17$3,000,000$118,500Equity, Option to Acquire
2011-06-24$2,750,000$219,500Equity
2010-11-08$2,000,000$634,500Equity, Other

Key Executives

  • Leuthner A. Brian
    Executive Officer, Director
  • Carl J. Soranno
    Director
  • R. Loch Macdonald
    Director
  • Brian Leuthner
    Executive Officer, Director, Promoter
  • Carl Sorrano
    Director, Promoter
  • R Loch McDonald
    Executive Officer, Director, Promoter
  • Sol Barer
    Director
  • Kurt Conti
    Director
  • James J. Loughlin
    Director
  • Bert Marchio
    Executive Officer, Promoter
  • Carl Soranno
    Executive Officer
  • Brian A. Leuthner
    Executive Officer, Director, Promoter
  • Sol J. Barer
    Director
  • James Loughlin
    Director
  • Robert Loch Macdonald
    Executive Officer, Director, Promoter
  • Isaac Blech
    Director
  • Priya Jambhekar
    Executive Officer
  • Albert N. Marchio II
    Executive Officer
  • Robert Spiegel
    Director
  • Andrew Einhorn
    Executive Officer
  • Herbert J. Faleck
    Executive Officer